Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paul G. Richardson, Susanna J. Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur S. Raje, Eva Medvedova, Philip L. McCarthy, Edward N. Libby, Peter M. Voorhees, Robert Z. Orlowski, Larry D. Anderson, David D. Hurd, Marcelo C. Pasquini, Kelly Masone, Philippe Moreau, Herve Avet-Loiseau, Michel Attal, Kenneth Carl Anderson, Nikhil C. Munshi
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, Winship Cancer Institute, Massachusetts General Hospital, Oregon Health & Science University, OHSU Knight Cancer Institute, Roswell Park Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, Levine Cancer Institute, The University of Texas MD Anderson Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Wake Forest University Health Sciences, Wake Forest University, Medical College of Wisconsin, Inserm, Centre de Recherches en Cancérologie de Toulouse, Institut universitaire du cancer de Toulouse Oncopole
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4293083208